Environmentally Responsive Ophthalmic Gel Formulation of Carteolol Hydrochloride

Environmentally responsive gel formulation for ocular controlled delivery of carteolol hydrochloride (HCl) was developed in an attempt to improve ocular bioavailability and hence decrease its systemic absorption and side effects. The viscosity and the ability of the prepared formulations to deliver carteolol HCl in vitro and in vivo were monitored and compared with an aqueous commercial solution. The effect of polymer concentration and drug concentration on the in vitro release of carteolol HCl was examined. Gelrite formulations showed pseudoplastic behavior with thixotropic characteristics and the viscosity of the prepared systems increased as the concentration of the polymer increased. At fixed drug concentrations, as the Gelrite concentration increased, the drug release decreased. At fixed polymer concentrations, as the drug concentration increased the release of drug increased. Gelrite formulation (0.4% w/w) containing 1% drug showed significantly improved bioavailability compared with the commercial aqueous solution (Arteoptic® 1%). The developed in situ gel formulation showed potential for use as delivery systems with superior ocular bioavailability of carteolol HCl.

[1]  T. S. Harrison,et al.  Ocular Carteolol , 2007, Drugs & aging.

[2]  H. Sasaki,et al.  Different Effects of Absorption Promoters on Corneal and Conjunctival Penetration of Ophthalmic Beta-Blockers , 1995, Pharmaceutical Research.

[3]  A. Tecante,et al.  Rheology-structure properties of gellan systems: evidence of network formation at low gellan concentrations , 2003 .

[4]  T. Järvinen,et al.  Cannabinoids in the treatment of glaucoma. , 2002, Pharmacology & therapeutics.

[5]  F. Agnely,et al.  Controlled release of vancomycin from poloxamer 407 gels. , 1999, International journal of pharmaceutics.

[6]  J. Carlfors,et al.  Rheological evaluation of Gelrite in situ gels for ophthalmic use. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  H. Sasaki,et al.  In‐situ Ocular Absorption of Ophthalmic β‐Blockers through Ocular Membranes in Albino Rabbits , 1997, The Journal of pharmacy and pharmacology.

[8]  Robert Gurny,et al.  PATENT LITERATURE REVIEW OF OPHTHALMIC INSERTS , 1995 .

[9]  E. Topp,et al.  Gellan-based systems for ophthalmic sustained delivery of methylprednisolone , 1993 .

[10]  A. Rozier,et al.  Gelrite®: A novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol , 1989 .

[11]  V. H. Lee,et al.  Topical ocular drug delivery: recent developments and future challenges. , 1986, Journal of ocular pharmacology.

[12]  S. G. Frank,et al.  In vitro release of lidocaine from pluronic F-127 gels , 1981 .

[13]  J F Griffith,et al.  Dose-response studies with chemical irritants in the albino rabbit eye as a basis for selecting optimum testing conditions for predicting hazard to the human eye. , 1980, Toxicology and applied pharmacology.

[14]  M. Saettone,et al.  A new method for determining the diffusion coefficient of drugs in semisolid vehicles from release data , 1979 .

[15]  W. Higuchi,et al.  Analysis of data on the medicament release from ointments. , 1962, Journal of pharmaceutical sciences.

[16]  M. A. Lauffer Theory of diffusion in gels. , 1961, Biophysical journal.

[17]  A. S. Lodge A network theory of flow birefringence and stress in concentrated polymer solutions , 1956 .